Meridian Medical Technologies

The product information provided in this site is intended only for emergency personnel and healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

(atropine and pralidoxime chloride injection)

You Are Now Leaving the MeridianMeds.com Website

Links to other sites are provided as a convenience to the viewer.

Pfizer accepts no responsibility for the content of linked sites.

CANCEL

Product image Mobile:

The ATNAA is a specially designed unit for self- or buddy-administration by military personnel. Atropine and pralidoxime chloride are administered sequentially to counteract organophosphorous nerve agents. While a victim can administer their own injection, a second or third injection might be needed and should be administered by a buddy.¹

Product indication:

Indication:

For the treatment of poisoning by susceptible organophosphorous nerve agents having anticholinesterase activity.

This product is only available for use by United States military personnel.

Please see full Prescribing Information.

Product Especification:

To order or request a quote, call 1-800-638-8093

Key Product Specifications²:
NSN	6505-01-362-7427
NDC	11704-777-01
Delivers	2.1 mg atropine in 0.7 mL and 600 mg pralidoxime chloride in 2 mL sequentially through a single needle using the two-chambered BinaJect® drug delivery system.
Length of Unit	145 mm
Diameter of Unit	19 mm
Needle Gauge	23
Needle Length	21 mm
Administration Type	Intramuscular injection
Packaged	100 auto-injectors per box
Packaging for Shipping	100 units per box (311 mm x 210 mm x 244 mm), weighing 5 kg 2 interior boxes (200 units) per shipper box (441 mm x 323 mm x 265 mm), weighing 10 kg
Storage	Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [See USP Controlled Room Temperature]. Keep from freezing. Protect from light.
Prescription Required	Yes

For medical:
Adverse Event or Product Quality Complaints
If you wish to report an adverse event or product quality complaint, please call 1-800-438-1985.

For medical questions concerning Meridian products, to report an adverse event, or to speak to a member of Pfizer US Medical Information, please call 1-800-438-1985.

You are encouraged to report side effects of prescription drugs to the FDA.
Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

Medical Information
If you have a medical question concerning Meridian products, please call 1-800-438-1985.
US HCPs can visit www.pfizermedinfo.com.

Product image Desktop:

Product trademark:

View full Prescribing Information for ATNAA (atropine and pralidoxime chloride injection) ORDER OR REQUEST A QUOTE

BinaJect® is a registered trademark of Meridian Medical Technologies, Inc., a Pfizer company.

Next Product:

PREVIOUS PRODUCT NEXT PRODUCT

Important Safety Information and Indication

IMPORTANT SAFETY INFORMATION AND INDICATION

Antidote Treatment Nerve Agent, Auto-Injector (ATNAA) (atropine and pralidoxime chloride injection)

The ATNAA Auto-Injector should be administered by military personnel who have had adequate training in the recognition and treatment of nerve agent intoxication. It is intended as an initial treatment of the symptoms of organophosphorous nerve agent poisoning; additional medical care should be sought as soon as possible.

Individuals should not rely solely upon agents such as atropine and pralidoxime when encountering a situation of nerve agent exposure. Primary protection against exposure to organophosphorous nerve agents is the wearing of protective garments including masks designed specifically for this use. Evacuation and decontamination procedures should be undertaken as soon as possible. Medical personnel assisting evacuated victims of organophosphorous nerve agent poisoning should avoid contaminating themselves by exposure to the victim's clothing.

In the presence of life-threatening poisoning by organophosphorous nerve agents there are no absolute contraindications to the use of ATNAA. When symptoms of poisoning are not severe, ATNAA should be used with extreme caution in people with heart disease, arrhythmias, recent myocardial infarction, severe narrow angle glaucoma, pyloric stenosis, prostatic hypertrophy, significant renal insufficiency, chronic pulmonary disease, or hypersensitivity to any compound of the product.

Severe difficulty in breathing requires artificial respiration in addition to the use of the ATNAA.

Pralidoxime is not effective in the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates not having anticholinesterase activity.

No more than three doses should be administered unless definitive medical care (eg, hospitalization, respiratory support) is available. Elderly people and children may be more susceptible to the effects of atropine. ATNAA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Safety and effectiveness in children have not been established.

Muscle tightness and sometimes pain may occur at the injection site. The most common adverse effects of atropine can be attributed to its antimuscarinic action and include dryness of mouth, blurred vision, dry eyes, photophobia, confusion, headache, and dizziness among others. Pralidoxime chloride's adverse effects include changes in vision, dizziness, headache, drowsiness, nausea, tachycardia, increased blood pressure, muscular weakness, dry mouth, emesis, rash, dry skin, hyperventilation, decreased renal function, excitement, manic behavior, and transient elevation of liver enzymes and creatine phosphokinase. When atropine and pralidoxime are used together, the signs of atropinization may occur earlier than might be expected when atropine is used alone.